Diabetes Research and Clinical Practice
Volume 74, Issue 2 , Pages 121-128 , November 2006

Association of gliclazide and left ventricular mass in type 2 diabetic patients

  • Nan-Hung Pan

      Affiliations

    • Cardiology Section, Department of Medicine, Taipei Medical University and Hospital, Taipei, Taiwan
    • These authors contributed equally to the paper.
    • ,
  • Tsung-Ming Lee

      Affiliations

    • Cardiology Section, Department of Medicine, Taipei Medical University and Chi-Mei Medical Center, Tainan, Taiwan
    • These authors contributed equally to the paper.
    • ,
  • Mei-Shu Lin

      Affiliations

    • Department of Pharmacy, National Taiwan University and Hospital, Taipei, Taiwan
    • ,
  • Chen-Ling Huang

      Affiliations

    • Endocrine Section, Department of Medicine, Taipei Medical University and Hospital, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author at: Cardiology Section, Department of Internal Medicine, Chi-Mei Medical Center, 901, Chung-Hwa Road, Yang-Kan City, Tainan 710, Taiwan. Tel.: +886 6 281 2811x52663; fax: +886 6 283 2639.
    • ,
  • Nen-Chung Chang

      Affiliations

    • Cardiology section, Department of Medicine, Taipei Medical University and Hospital, Taipei, Taiwan

Received 2 January 2006 ,Accepted 15 March 2006.

References 

  1. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19:257–267
  2. Tu VC, Bahl JJ, Chen QM. Signals of oxidant-induced cardiomyocyte hypertrophy: key activation of p70 S6 kinase-1 and phosphoinositide 3-kinase. J. Pharmacol. Exp. Ther. 2002;300:1101–1110
  3. Higuchi Y, Otsu K, Nishida K, Hirotani S, Nakayama H, Yamaguchi O, et al. Involvement of reactive oxygen species-mediated NF-kappa B activation in TNFα-induced cardiomyocyte hypertrophy. J. Mol. Cell. Cardiol. 2002;34:233–240
  4. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J. Hypertens. 2002;18:655–673
  5. Schaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am. J. Hypertens. 1998;11:1394–1404
  6. Date MO, Morita T, Yamashita N, Nishida K, Yamaguchi O, Higuchi Y, et al. The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. J. Am. Coll. Cardiol. 2002;39:907–912
  7. Morrow JD, Minton TA, Badr KF, Roberts LJ. Evidence that the F2-isoprostane, 8-epi-prostaglandin F2α, is formed in vivo. Biochim. Biophys. Acta. 1994;1210:244–248
  8. Morrow JD, Minton TA, Mukundan CR, Campbell MD, Zackert WE, Daniel VC, et al. Free radical-induced generation of isoprostanes in vivo. Evidence for formation of D-ring and E-ring isoprostanes. J. Biol. Chem. 1994;269:4317–4326
  9. Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, et al. In vivo formation of 8-epi-prostaglandin F2α is increased in hypercholesterolemia. Arterioscl. Thromb. Vasc. Biol. 1997;17:3230–3235
  10. Mueller T, Dieplinger B, Gegenhuber A, Haidinger D, Schmid N, Roth N, et al. Serum total 8-iso-prostaglandin F2α: a new and independent predictor of peripheral arterial disease. J. Vasc. Surg. 2004;40:768–773
  11. Onozato ML, Tojo A, Goto A, Fujita T. Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. Kidney Int. 2004;65:951–960
  12. Noda Y, Mori A, Cossins E, Packer L. Gliclazide scavenges hydroxyl and superoxide radicals: an electron spin resonance study. Metabolism. 2000;49(2 Suppl. 1):14–16
  13. Kirdendall WM, Feinleib MH, Freis ED, Mark AL. Recommendation for human blood pressure determination by sphygmomanometers. Hypertension. 1981;3:509A–519A
  14. Lee TM, Su SF, Chen MF, Liau CS, Lee YT. Effects of increasing flow rate on aortic stenotic indices: evidence from percutaneous transvenous balloon dilation of the valve in patients with combined aortic and mitral stenosis. Heart. 1996;76:490–494
  15. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 1986;57:450–458
  16. Sohn DW, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH, et al. Assessment of mitral annulus velocity by doppler tissue imaging in the evaluation of left ventricular diastolic function. J. Am. Coll. Cardiol. 1997;30:474–480
  17. Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin F2α formation. J. Cardiovasc. Pharmacol. 2002;40:868–874
  18. Allain LA, Poon LS, Chan LSG, Richmond W, Fu PL. Enzymatic determination of total serum cholesterol. Clin. Chem. 1974;20:470–475
  19. Warnick GR, Knopp RH, Fitzppatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin. Chem. 1990;36:15–19
  20. Desfaits AC, Serri O, Renier G. Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL. Metabolism. 1997;46:1150–1156
  21. Ilercil A, Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, et al. Associations of insulin levels with left ventricular structure and function in American Indians: the strong heart study. Diabetes. 2002;51:1543–1547
  22. Morissette MR, Howes AL, Zhang T, Heller Brown J. Upregulation of GLUT1 expression is necessary for hypertrophy and survival of neonatal rat cardiomyocytes. J. Mol. Cell. Cardiol. 2003;35:1217–1227
  23. Kunapuli P, Lawson JA, Rokach JA, Meinkoth JL, FitzGerald GA. Prostaglandin F2α (PGF2α) and the isoprostane, 12-iso-isoprostane F2α-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J. Biol. Chem. 1998;273:22442–22452
  24. Adams JW, Migita DS, Yu MK, Young R, Hellickson MS, Castro-Vargas FE, et al. Prostaglandin F2α stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. J. Biol. Chem. 1996;271:1179–1186
  25. Lai J, Jin H, Yang R, Winer J, Li W, Yen R, et al. Prostaglandin F2α induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am. J. Physiol. 1996;271:H2197–H2208
  26. Darko D, Dornhorst A, Kelly FJ, Ritter JM, Chowienczyk PJ. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in Type II diabetes. Clin. Sci. (Lond.). 2002;103:339–344
  27. Schwedhelm E, Boger RH. Application of gas chromatography–mass spectrometry for analysis of isoprostanes: their role in cardiovascular disease. Clin. Chem. Lab. Med. 2003;41:1552–1561
  28. Babenko AP, Bryan J. A conserved inhibitory and differential stimulatory action of nucleotides on KIR6.0/SUR complexes is essential for excitation-metabolism coupling by KATP channels. J. Biol. Chem. 2001;276:49083–49092
  29. Gribble FM, Ashcroft FM. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from β cells and extrapancreatic tissues. Metabolism. 2000;49(10 Suppl 2):3–6
  30. Geisen K, Vegh A, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm. Metab. Res. 1996;28:496–507
  31. Lee TM, Lin MS, Chou TF, Tsai CH, Chang NC. Effect of pravastatin on left ventricular mass by activation of myocardial KATP channels in hypercholesterolemic rabbits. Atherosclerosis. 2004;176:273–278
  32. Xia Y, Rajapurohitam V, Cook MA, Karmazyn M. Inhibition of phenylephrine induced hypertrophy in rat neonatal cardiomyocytes by the mitochondrial KATP channel opener diazoxide. J. Mol. Cell. Cardiol. 2004;37:1063–1067
  33. Sanada S, Node K, Asanuma H, Ogita H, Takashima S, Minamino T, et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase. J. Am. Coll. Cardiol. 2002;40:991–997
  34. Gottdiener JS, Livengood SV, Meyer PS, Chase GA. Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function. J. Am. Coll. Cardiol. 1995;25:424–430

PII: S0168-8227(06)00110-0

doi: 10.1016/j.diabres.2006.03.009

Diabetes Research and Clinical Practice
Volume 74, Issue 2 , Pages 121-128 , November 2006

Article Tools

* Image Usage & Resolution